V ascular smooth muscle cells (SMCs) contract in response to neurostimulation and biomechanical forces of pulsatile blood flow, a process that involves cyclic interactions of the thick and thin filaments of the actomyosin system. Thin filaments are composed of polymers of the smooth muscle-specific isoform of α-actin (SM α-actin), which accounts for 40% of total cellular protein in SMCs. Heterozygous mutations in the corresponding gene (ACTA2) predispose to thoracic aortic aneurysms, acute aortic dissections, and occlusive vascular diseases, such as premature onset stroke and coronary artery disease and moyamoya disease. [1] [2] [3] The majority of ACTA2 mutations leading to familial thoracic aortic disease are missense mutations predicted to produce a mutant α-actin monomer. SMCs explanted from patients with ACTA2 missense mutations have fewer filaments of SM α-actin than wild-type (WT) SMCs, suggesting a dominant negative effect of the mutant protein on filament formation. 1 More detailed in vitro studies assessing the effects of a recurrent ACTA2 missense mutation, R258C, indicate that the mutation alters filament formation and stability and impairs interactions with myosin, all of which are predicted to decrease the number of SM α-actin filaments and force generation by SMCs. June 9, 2017 of SMCs. 6 Initial studies indicated that blocking transforming growth factor-β signaling prevents aneurysm growth in this mouse model, 5 and more recent studies have suggested that transforming growth factor-β activation of ERK1/2 (extracellular signal related kinase) signaling also contributes to disease. 7 Both Smad2 and ERK1/2 can be activated by either transforming growth factor-β or angiotensin II (AngII) signaling, and the fact that an AngII type I receptor (Agtr1a) blocking agent, losartan, rescues aneurysms formation in the Marfan mouse model suggests that Agtr1a activation contributes to aneurysm formation. Other mouse models support this hypothesis, including the Fbln4 SMC-specific knockout (Fbln4 SMKO ) mouse model and mouse models of Loeys-Dietz syndrome with either Tgfbr1 or Tgfbr2 missense mutations. 8, 9 Although increased tissue levels of AngII in the aortas of Fbln4 SMKO mouse are proposed as the source of AngII signaling in the Fbln4 SMKO mouse model, the pathogenesis of the excessive Agtr1a activity has not been identified in the Marfan or Loeys-Dietz mouse models.
In this study, Acta2 −/− mice are used to explore how loss of SM α-actin leads to thoracic aortic enlargement.
Acta2
−/− mice have normal vascular development but are hypotensive and have decreased aortic contraction in response to agonist stimulation. 10 Previous studies determined that loss of SM α-actin increases SMC proliferation in vitro and in vivo through increased focal adhesion kinase activity driving increased reactive oxygen species (ROS) levels and platelet-derived growth factor receptor β signaling. 11 We describe here Agtr1a-dependent aortic root enlargement in the Acta2 −/− mouse with no evidence of increased levels of AngII in the Acta2 −/− aortic or renal tissues. Instead, we demonstrate that loss of SM α-actin in SMCs increases cellular ROS levels, which increases nuclear factor (NF)-κB signaling, leading to increased expression of Agtr1a. These cellular changes result in increased AngII signaling in mutant aortic SMCs, which contributes to aortic root enlargement without increased AngII levels.
Methods

Mouse Studies
All mouse experiments were performed in accordance with institutional guidelines set forth by the University of Texas Health Science Center at Houston Animal Welfare Committee. Standard methods were used to rederive Acta2 −/− mice (C57/Bl6 background) from frozen embryos obtained from Dr Warren Zimmer at Texas A&M University. Agtr1a −/− mice were purchased from The Jackson Laboratory (strain B6.129P2-Agtr1a tm1Unc /J.). For all animal treatment trials, sample sizes were determined using a statistical power calculator based on the initial observed effect size. Doses and time points for drug treatments in animal models were based on published protocols. All mice underwent echocardiography at 4 weeks of age and then were randomly assigned to control or treatment groups. Losartan (Santa Cruz Biotechnology, cat no. sc-204796A) was administered at 0.6 g/L in the drinking water for 6 months, with echocardiography performed every 8 weeks, and aortas harvested for histology at the end of the study. Shorter treatments were used for RNA and protein analysis to eliminate possible secondary effects. N-acetyl cysteine (NAC; Sigma, Cat no. A9165) was administered at 500 mg/kg per day in 
Novelty and Significance
What Is Known?
• Mutations in ACTA2 cause thoracic aortic aneurysms and dissections.
• An angiotensin II (AngII) type 1 receptor blocker (losartan) reduces or prevents aortic disease in multiple mouse models of thoracic aortic aneurysms.
• Smooth muscle cells (SMCs) explanted from the ascending aorta of Acta2 −/− mice have increased cellular levels of reactive oxygen species (ROS).
What New Information Does This Article Contribute?
• Losartan treatment attenuates aortic root enlargement in Acta2 −/− mice, but there is no evidence of increased AngII levels in the aorta or kidneys.
• The higher ROS levels in Acta2 −/− SMCs drives increased expression of the AngII receptor type I a via nuclear factor κB signaling, leading to activation of AngII signaling in aortic SMCs at 100-fold lower levels of AngII than required to activate signaling in wild-type SMCs.
This study was initiated to investigate the mechanism of thoracic aortic aneurysm formation associated with mutations in ACTA2, the gene encoding the smooth muscle isoform of α-actin. We show that Acta2 −/− mice have aortic root dilatation, which is attenuated by treatment with an AngII type 1 receptor blocker (losartan). We did not find increased levels of AngII in the aorta or kidney of Acta2 −/− mice. Instead, we show that Acta2 −/− SMCs activate signaling at 100-fold lower levels of AngII when compared with wild-type cells because of increased expression of AngII receptor type I a. We go on to show that the increase in cellular ROS in Acta2 −/− SMCs activates nuclear factor κB signaling, which drives expression of both AngII receptor type I a and Nox4, further increasing ROS generation. Importantly, we show that this signaling mechanism is initiated in wild-type SMCs when smooth muscle isoform of α-actin filaments are disrupted by other methods. Taken together, our results show a mechanism by which increased AngII type I receptor signaling in aortic SMCs can drive aortic aneurysm formation without an increase in exogenous AngII levels, and this mechanism may underlie aneurysm formation because of other causes. Furthermore, inhibition of ROS or nuclear factor κB signaling may be a viable therapeutic strategy for preventing aneurysm formation.
drinking water. For all protein and mRNA analyses, only ascending aortic tissue was used.
SMC Isolation and Culture
SMCs were explanted from the ascending aortas of age-and sexmatched Acta2 −/− and WT littermates as previously described. 
Results
Morphological Characterization of the Post-Natal Ascending Thoracic Aorta in the Acta2 −/− Mice
We found that the Acta2 −/− aortas have increased elastin lamellae when compared with WT aortas ( Figure 1A and 1B), which is similar to the increase in elastic lamellae layers observed in the Eln +/− mice. 12 At 4 weeks of age, the density of cells staining positive for a SMC marker, calponin, in the medial layer was also higher in the Acta2 −/− aortas ( Figure 1A and 1B). Despite evidence for increased SMC density, the levels of several contractile proteins in Acta2 −/− aortas were similar to WT aortas, including smooth muscle myosin heavy chain, calponin, and SM22α ( Figure 1C ; Online Figure IA) . Although SM α-actin is absent, immunoblot with a pan-actin antibody found no difference in total actin levels between Acta2 −/− and WT aortas, suggesting compensation by another actin isoform. Using 2-dimensional gel analysis, we confirmed the ectopic expression of an actin isoform at the same isoelectric point with SM α-actin (Online Figure IB and IC) . Mass spectrometry analysis of the additional actin expressed in the Acta2 −/− SMCs failed to distinguish between cardiac and skeletal muscle α-actins, but quantitative polymerase chain reaction determined increased expression of Acta1 (Online Figure  ID) . Thus, skeletal α-actin expression compensates for the loss of SM α-actin in Acta2 −/− SMCs. Electron microscopic analysis of the WT aorta showed oblique elastin extensions that link to the intracellular contractile filaments in the SMCs through dense plaques on the cell surface, as previously described (red arrows, Figure 1D ). 6 In contrast, the Acta2 −/− aortas had increased space and fewer connections between the SMCs and elastin fibers, no contractile filaments within the cell, and improper orientation of the SMCs to the elastin fibers ( Figure 1D ). The focal adhesions linking the microfibrils at the periphery of the elastin fibers to the contractile units were greatly decreased in the Acta2 −/− aortas. At the same time, there was the appearance of submembranous dense aggregates in the SMCs that were not present in the WT aortas (green arrows, Figure 1D ). At 6 months of age, electron microscopy of the Acta2 −/− mouse aortas continued to show a lack of connections between the abnormal-appearing SMCs and elastin fibers with increased extracellular matrix material built up in the space between the cells and the elastin fibers ( Figure 1E ). Taken together, the post-natal Acta2 −/− aortas are morphologically characterized by increased numbers of elastin lamellae and SMCs, and there are ultrastructural abnormalities that include decreased connections to the elastin lamellae, loss of intracellular contractile filaments, and the appearance of submembranous dense structures.
Aortic Root Dilation Is Attenuated by Losartan in the Acta2
−/− Mice Echocardiography showed no difference between 4-week-old WT and Acta2 −/− mice in the root or ascending aortic diameters (Online Figure IIA) . However, by 6 months of age, the Acta2 −/− mice had significant enlargement of the aortic root when compared with WT mice, despite hypotension in the Acta2 −/− mice ( −/− mice and WT littermates, suggesting that the aortic enlargement does not progress to aortic dissection (Online Figure IID) . In addition, the area of the medial layer in Acta2 −/− aortas increased with age and was significantly greater than the WT by 12 months of age ( Figure 2B ). Despite early differences, by 3 months of age, medial cell densities were comparable between the Acta2 −/− and WT aortas, and the densities remain similar up to 12 months of age ( Figure 2C ).
We sought to determine whether treatment with losartan would block aortic dilation in the Acta2 −/− mice. Losartan treatment was initiated at 1 month of age and continued for 6 months. Aortic growth was attenuated in the Acta2 −/− mice based on the fact that the aortic root diameter in the treated mice is no longer significantly different than the WT mice, whereas the untreated Acta2 −/− aortic root diameters are significantly enlarged ( Figure 2D ). Pathological analysis at 7 months of age showed minimal medial degeneration with significantly increased deposition of proteoglycans in the mutant mice, which is decreased by losartan ( Figure 2E ; Online Figure IIIA) .
Canonical transforming growth factor-β signaling and ERK1/2 activation were increased in the thoracic aortas of the Marfan mouse model, and this activation is reversed with losartan. 5, 7 We sought to determine whether these same pathways were altered in the Acta2 −/− aortas but also wanted a marker for AngII signaling. With exposure to AngII, SMCs rapidly phosphorylate RelA (pRelA) at serine 536 through a Rho-dependent pathway; thus, pRelA was also assessed as a marker of NF-κB activation because of AngII. 13 Lysates from the Acta2 −/− aortas showed increased levels of pRelA and pERK (phosphorylated ERK), but only pRelA levels were attenuated with losartan treatment; the Acta2 −/− aortas had no increase in pSmad2/3 ( Figure 2G ; Online Figure IIIB) . Expressions of several pathological markers, including Il6, Mmp2, and Mmp9, were increased in Acta2 −/− aortic tissue, and the expressions of these genes are significantly decreased with losartan treatment ( Figure 2F ).
Because losartan attenuates aortic dilation, AngII levels and expression of the genes encoding proteins involved in AngII production were assessed in these mice. Although Fbln4 SMKO mice had increased AngII in the aortic tissue, AngII levels in Acta2 −/− mice were not increased compared with WT in either the aorta or kidneys ( Figure 2H ). Instead, we found that Agtr1a expression was increased in the Acta2 −/− aortas and was not significantly decreased by losartan treatment ( Figure 2I ). Agtr1b expression levels are 8-fold less than Agtr1a levels (comparison not shown) but were also increased in the mutant aortas and decreased by losartan.
Increased Blood Pressure Augments Aortic Enlargement in Acta2 −/− Mice
As previously reported, Acta2 −/− mice are hypotensive (WT mice, systolic 114.4±9.5, versus Acta2 −/− mice, 82.2±6.4 mm Hg). 10 To determine whether hypotension in the Acta2 −/− mice limits aortic enlargement, blood pressure was raised to WT levels by feeding 4-week-old Acta2 −/− mice a nitric oxide synthesis inhibitor, L-N G -nitroarginine methyl ester (L-NAME), and a high-salt diet ( Figure 6F ). Raising the blood pressure significantly accelerated the growth of both the aortic −/− mice shows comparable levels of aortic SMC contractile protein expression at 4 wk of age. Smooth muscle α-actin (SM α-actin) is absent in Acta2 −/− aortas as expected, but another actin isoform is expressed to compensate based on similar pan-actin levels for both genotypes. Electron microscopy analysis of Acta2 −/− aortas at 4 wk (D) and 6 mo (E) of age shows a lack of contractile filaments (CF) within SMCs, aberrant connections between the cells and the elastin fibers (EL), and submembranous dense plaques (green arrows) rather than focal adhesions (red arrows; n=2 mice per genotype per time point). H&E indicates hematoxylin and eosin; and MHC, myosin heavy chain.
root and ascending aorta in the Acta2 −/− mice by 3 months of age, suggesting that aortic dilatation in the mutant mice is dependent on the biomechanical forces on the aorta ( Figure 6G ). We also attempted to increase the hemodynamic forces on the aorta in the Acta2 −/− mice through thoracic aortic constriction, but the hypotensive mice died with the induction of anesthesia.
Acta2 −/− SMCs Have Increased ROS Levels and Basal NF-κB Signaling and Increased Sensitivity to Exogenous AngII
To investigate the increased signaling through the Agtr1a in Acta2 −/− mice, SMCs were explanted from the ascending aorta. Our previous studies determined that Acta2 −/− SMCs have −/− aortas is significantly increased at 4 wk of age when compared with WT aortas, but then normalizes and remains equal to cell density to the WT aorta from 8 wk to 12 mo of age. Medial area and cell density were quantified from hematoxylin and eosin-stained histology slides (n=3 or more per genotype, *P<0.05, error bars represent SEM). D, Treatment with losartan attenuates aortic root dilation of Acta2 −/− mice as measured by echocardiography. Losartan treatment was initiated at 4 wk of age and continued for 6 mo (n=15 WT; n=12 Acta2 −/− ; n=9 Acta2 −/− +losartan). E, Histological stains of Acta2 −/− aortas show minimal medial degeneration at 7 mo of age (n=7 or more mice per group). F, Losartan treatment significantly reduced the increased expression of the Il6, Mmp2, and Mmp9 genes in Acta2 −/− aortas. G, Western blot of Acta2 −/− aortas shows increased pRelA and increased pERK1/2 (phosphorylated extracellular signal related kinase) signaling relative to WT, but no change in Smad signaling. Losartan treatment reduces phosphorylated RelA (pRelA) levels, but not pERK1/2 levels. H, Levels of AngII in Acta2 −/− aortas and kidneys are not significantly different from WT. Measurements were made at 3 mo of age (n=20 aortas per genotype, 4 kidneys per genotype). I, Several components of the renin-angiotensin system are differentially expressed in Acta2 −/− aortas, including upregulation of Enpep, Agtr1a, and Agtr1b and decreased expression of renin. Only Enpep and Agtr1b were reversed by losartan treatment. For F and I, lysates were harvested at 8 wk of age, losartan treatment initiated at 4 wk, n=3 aortas per group.
increased levels of cellular ROS and ERK1/2 signaling. 11 To determine whether Acta2 −/− SMCs are more responsive to exogenous AngII, we assessed pRelA levels. Surprisingly, Acta2 −/− SMCs show activated pRelA in the absence of AngII, whereas WT SMCs do not ( Figure 3A) , and this increased pRelA signaling correlates with increased Il6 expression in the Acta2 −/− SMCs (Online Figure VC) . Furthermore, the Acta2 −/− SMCs show increased sensitivity to AngII and prolonged signaling. In the Acta2 −/− SMCs, pRelA levels increase at 10 nmol/L AngII, whereas pRelA levels do not increase in WT SMCs until a 100-fold higher dose of AngII is used (1000 nmol/L; Figure 3A ; Online Figure IVA) . The Acta2 −/− SMCs are also more sensitive than WT SMCs to exogeneous AngII based on intracellular Ca 2+ assays ( Figure 3B ). The Acta2 −/− SMCs show earlier and more prolonged increases in pRelA levels than WT SMCs when exposed to 1 µmol/L AngII (Online Figure IVB and IVC) . Similar to the Acta2 −/− aortas, expression of Agtr1a is increased >8-fold in the Acta2 −/− SMCs ( Figure 3D ). For all cellular studies, Agtr1b expression followed the same pattern as Agtr1a but is ≈10-fold lower (data not shown).
We sought to determine the signaling pathway responsible for increased Agtr1a expression and AngII sensitivity in the Acta2 −/− SMCs. Inhibition of the Agtr1a using losartan effectively blocks the increase of pRelA in response to exogenous AngII but does not decrease the basal level of pRelA in Acta2 −/− SMCs; Il6 expression with these treatments correlates with pRelA levels (Online Figure VA through VC) .
AngII-induced NF-κB activation in SMCs is mediated by RhoA/ROCK (Rho-associated protein kinase) phosphorylation of Ser536 of RelA. 13 Therefore, Acta2 −/− SMCs were exposed to Clostridium botulinum exoenzyme C3 exotoxin to block Rho activation, which blocks AngII-inducible pRelA as expected, but does not decrease baseline activation of RelA in the Acta2 −/− SMCs (Online Figure VD and VE) . ROS is a known activator of NF-κB signaling, and we previously found increased cellular ROS levels in the Acta2 −/− SMCs.
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Blocking cellular ROS using NAC decreases the baseline pRelA levels in the Acta2 −/− SMCs and reduces the sensitivity of these cells to exogenous AngII ( Figure 3C ; Online Figure  VF) . NAC treatment also decreases the expression of Agtr1a, Il6, and Mmp2 in the mutant SMCs to levels similar to WT SMCs ( Figure 3D ). Finally, pre-treatment of cells with NAC abolishes the increase in intracellular calcium in response to exogenous AngII in both WT and Acta2 −/− SMCs ( Figure 3E ). To confirm that NF-κB signaling is responsible for the hypersensitivity of the Acta2 −/− SMCs, these cells were treated with an NF-κB inhibitor anatabine, which partially blocked phosphorylation of RelA and also reduced expression of Il6, Agtr1a, and Mmp2 to levels similar to WT cells (Online Figure  VIA and VIB).
14 Helenalin, an inhibitor of NF-κB DNA binding activity, which does not affect RelA phosphorylation, also significantly blocks expression of Il6, Agtr1a, and Mmp2 ( Figure 4A) . 15, 16 In addition, pre-treatment of cells with either anatabine or helenalin abolishes the increase in intracellular calcium in response to exogenous AngII in both WT and Acta2 −/− SMCs ( Figure 4B ). To identify the source of increased ROS, the expressions of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidases were assessed, and expressions of Nox4 and p22 phox , along with a known activator of Nox4, Poldip2, are all significantly increased in the Acta2 −/− SMCs ( Figure 4C ). 17, 18 There is no significant change in expression of Nox1 or Nox2 (Online Figure VIC) . Furthermore, a specific inhibitor of Nox4, VCC588646, reduces ROS levels in Acta2 −/− SMCs and also significantly decreases expression of Il6, Mmp2, and Agtr1a ( Figure 4D and 4E) . 19 NF-κB has been previously shown to directly induce Nox4 expression, 20 and treatment with helenalin significantly reduces expression of Nox4, Poldip2, and p22 phox in Acta2 −/− SMCs ( Figure 4F ). Taken together, our data suggest a feedback loop in which increased ROS levels drive NF-κB signaling that increases Nox4, p22 phox , and Poldip2 expression and ROS accumulation. This feedback loop increases expression of Agtr1a leading to increased AngII sensitivity in the aortic SMCs.
Disruption of SM α-Actin Filaments in WT SMCs Increases Expression of the Agtr1a and Sensitivity to Exogenous AngII
Previous studies showed that loss of another contractile protein in mouse SMCs, SM22α, also increased ROS and NF-κB signaling in SMCs. 21 To further explore whether disrupting the SMC cytoskeletal/contractile structure increases NF-κB signaling in SMCs, SMCs were treated with latrunculin B, a drug that rapidly and specifically disrupts the cytoskeleton by inhibiting actin polymerization. Latrunculin effectively disrupts F actin formation detected by phalloidin staining in WT SMCs and increases pRelA levels (Figure 5A and 5B; Online Figure VIIA) . Cotreatment with NAC blunts the increase in pRelA with latrunculin treatment, suggesting that the mechanism identified in Acta2 −/− cells is also applicable here ( Figure  5C ; Online Figure VIIB) .
To further study activation of NF-κB signaling with loss of SM α-actin, a cell permeable peptide that disrupts SM α-actin filaments (αSMA-fp) in WT SMCs was obtained, along with a control peptide directed against α-skeletal actin (αSKA-fp) that minimally disrupts SM α-actin filaments ( Figure 5D ). 22 The αSMA-fp peptide treatment in WT SMCs, but not αSKA-fp, significantly increases pRelA levels in WT SMCs, providing further support that specific disruption of α-actin filaments activates NF-κB signaling in SMCs ( Figure 5E ; Online Figure  VIIC ). Similar to the Acta2 −/− SMCs, activation of NF-κB signaling with αSMA-fp treatment in WT SMCs increases expression of Agtr1a, Il6, and Mmp2 but the αSKA-fp peptide does not ( Figure 5F ). Taken together, these results indicate that disruption of SM α-actin filaments drives NF-κB signaling and increases Agtr1a expression.
Increased ROS in Acta2 −/− Aortas
Based on the increased ROS and NF-κB signaling in the Acta2 −/− SMCs in vitro, we sought to determine whether ROS was increased in the Acta2 −/− aortas using dihydroethidium staining. 23 Acta2 −/− aortas have increased dihydroethidium staining when compared with WT aortas, and this increased staining was decreased when the Acta2 −/− mice were treated with NAC for 3 weeks ( Figure 6A ). In addition, NADPH oxidase activity was significantly increased in the mutant aortas ( Figure 6B ). Similar to the explanted Acta2 −/− SMCs, the Acta2 −/− aortas have increased expression of Nox4 ( Figure  6C ), but the expressions of the other NADPH oxidase subunits were not significantly changed (Online Figure VIIIA) . To confirm the role of ROS in driving signaling changes in the Acta2 −/− aortas, we treated Acta2 −/− mice with NAC for 3 weeks starting at 4 weeks of age. The expressions of Mmp2, Il6, and Agtr1a are both significantly reduced after NAC treatment ( Figure 6E) . Furthermore, treatment with NAC blocks the increase in pRelA but not the increased phosphorylation of ERK1/2 ( Figure 6D ; Online Figure VIIIB and VIIIC) . We used Acta2 −/− mice treated with L-NAME and high-salt diet to assess whether NAC treatment would prevent aortic dilation.
Acta2
−/− mice cotreated with NAC and L-NAME with highsalt diet no longer had significant dilation of the ascending aorta at 3 months of age, but the growth of the aortic root was not reversed by NAC treatment ( Figure 6G ).
Because AngII signaling increases superoxide production by activation of NADPH oxidases in SMCs, 24 we crossed the with Acta2 −/− levels but is still significantly higher than WT levels ( Figure 7A) . Similarly, NADPH oxidase activity in Acta2
−/− aortas is not significantly different from either Acta2 −/− or WT aortas, suggesting that the addition of the Agtra1 knockout partially but incompletely blocks ROS production ( Figure 7B ). Furthermore, Mmp2 expression remains significantly higher in the double knockout compared with WT aortas (Figure 7D ). It is important to note that the Agtr1b expression in the Acta2 −/− Agtr1a −/− aorta is similar to the levels observed in the Agtr1a −/− aortas ( Figure 7E ). These data support the conclusion that ROS is elevated in the Acta2 −/− mice even in the absence of AngII signaling through the Agtr1a receptor.
Discussion
The studies reported here found that loss of SM α-actin in vascular SMCs increases ROS and activates NF-κB signaling, −/− aortas were also reduced by NAC treatment (n=5 per group). E, NAC treatment decreases the increased expression of Mmp2, Il6, and Agtr1a (n=3 per group). F, Acta2 −/− mice have significantly lower systolic blood pressure than WT; treatment with L-N G -nitroarginine methyl ester (L-NAME) and high-salt diet increases blood pressure in Acta2 −/− mice to WT levels (n=6 or more mice per group). G, Treatment with L-NAME and high-salt diet significantly increases aortic root and ascending aortic dilation by 3 mo of age. Cotreatment with NAC reduces ascending aortic enlargement (P=0.057 for L-NAME vs L-NAME+NAC groups) but does not prevent aortic root enlargement (n=9 WT; n=12 Acta2 −/− aortic SMCs in vivo have elevated ROS and NF-κB signaling at baseline that sensitizes these cells to exogenous AngII, driving a feedback loop resulting in further increases in ROS and NF-κB signaling (Online Figure IX) . Previous studies found that when ROS is increased in SMCs through the overexpression of p22 phox , AngII-driven aortic SMC hypertrophy is potentiated. 25 Our data suggest that the increased cellular ROS in the p22 phox -overexpressing SMCs may activate NF-κB signaling and increase expression of Agtr1a, thus potentiating AngII signaling in aortic SMCs.
SM22α plays a critical role in regulating and stabilizing the actin cytoskeleton in SMCs, and loss of SM22α in SMCs increases ROS and triggers NFκB signaling. 21, 26 Similar to our results, loss of SM22α enhanced AngII signaling, but the pathogenesis of this enhanced signaling was not identified. 27 Based on our data, increased Agtr1a expression driven by NF-κB signaling should be responsible for the enhanced AngII signaling in these cells. Taken together with our data, loss of cytoskeletal/contractile elements in vascular SMCs can lead to enhanced AngII signaling. The pathogenesis of the excessive Agtr1a signaling in the aortas of the Marfan and LoeysDietz mouse models has not been identified. ROS levels are increased in both the aortas and explanted SMCs of Marfan mouse models. 28, 29 Once again, this increase of ROS may lead to NF-κB-dependent increase of Agtr1a expression and contribute to aneurysm formation in the Marfan mouse model.
We observed increased expression of Nox4, p22phox, and a specific activator of Nox4 Polydip2, in the Acta2 −/− SMCs, and inhibition of NF-κB signaling rescues this overexpression. Our data support a feedback loop where increased ROS leads to increased NF-κB activation, which then drives expression of Nox4, p22phox, and Polydip2 and further increases ROS production. NF-κB has been previously shown to bind to the Nox4 promoter to drive its expression directly. 20 Like NF-κB inhibition, a specific inhibitor of Nox4 used short-term (12 hours) decreased cellular ROS and decreased expression of Il6, Mmp2, and Agtr1a, 19 suggesting that inhibiting the feedback loop at either point can successfully break the cycle and prevent the downstream effects. However, conclusively confirming the role of Nox4 activity in ROS production is complicated by the fact that loss of Nox4 leads to dedifferentiation of SMCs. 30 We cannot rule out that loss of SM α-actin activates other pathways that contribute to elevated ROS. Previous studies found that loss of SM22α in SMCs leads to actin filament depolymerization and activation of the PKCδ-p47 phox axis, driving ROS production, 27 and this pathway could potentially be the source of the initial increase in ROS driving NF-κB signaling in the Acta2 −/− SMCs. The Acta2 −/− mice have dilation of the aortic root by 6 months of age, similar to the enlargement of the aortic root observed in patients with ACTA2 mutations, 31 and aortic root dilation is attenuated but not reversed with losartan, an Agtr1a blocking agent. Blocking the Agtr1a through treatment with losartan attenuates pRelA signaling but not ERK1/2 signaling. In addition, ROS levels remain elevated with knockout of the Agtr1a receptor in the Acta2 −/− mice, suggesting that increases in ROS and downstream molecular changes are independent of exogenous AngII signaling through the Agtr1a in the Acta2 −/− aortic SMCs. Thus, increased ROS and ERK1/2 signaling may be responsible for the incomplete rescue of aortic enlargement with losartan treatment. It is important to note that the significant hypotension of Acta2 −/− mice limits aortic enlargement based on the observation that there is increased rate of growth of the aorta when the blood pressure is raised to normal levels using L-NAME and a high-salt diet. It is notable that the current data suggest that blocking nitric oxide signaling protects the aorta from enlargement in mouse models of aneurysms, 32 and excessive signaling through a downstream target of nitric oxide signaling, type I cGMPdependent protein kinase, can drive thoracic aortic disease. 33 Therefore, there is no evidence that L-NAME contributes to aortic growth; rather the increased blood pressure drives more rapid growth of the aorta.
In the Acta2 −/− post-natal aorta, we found increased elastin lamellar units and a greater number of SMCs. A similar increase in lamellar units is found in mice hemizygous for elastin (Eln
+/−
). 12 Furthermore, humans with ELN hemizygosity also show an increase in elastin lamellae associated with supravalvular aortic stenosis. 34, 35 The number of lamellar units is species specific and fixed during development. Based on anatomic and physiological studies showing that the relationship between wall stress and the number of lamellar units in an artery, the ratio is remarkably constant across species despite variation in arterial diameter, supporting that the number of elastin lamellae in different species is evolutionarily dictated by the wall stress. 36 Therefore, the increased lamellar units in the Eln +/− and Acta2 −/− mice may be because of altered wall stress resulting from underlying deficiencies during development. The Eln +/− mice are hypertensive, which may contribute to the increased wall stress and therefore the increased numbers of elastin lamellae. 37 However, the Acta2 −/− mice are hypotensive, and the source of the wall stress is not known.
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Acta2
−/− SMCs are stiffer in culture than WT SMC, 11 suggesting that cellular stiffness rather than global wall stress may be responsible for the increased lamellar units in the Acta2 −/− aortas. By electron microscopy, the SMCs in the Acta2 −/− aortas have dense submembranous structures of unknown pathogenesis that are not present in the WT SMCs. SMC contraction requires 2 independent processes: polymerization of actin filaments and actomyosin cross-bridge cycling. 38 With SMC contraction, a small pool of submembranous actin at extracellular matrix/cytoskeletal junctions polymerizes and fortifies the connection between the membrane integrin receptors and the actin in the contractile thin filaments, which remain stably polymerized. The cortical actin and its associated cytoskeletal network provide a rigid structure for transmission of tension generated by the actomyosin cross-bridge cycling in the contractile filaments extending across the cell. The SMCs in the Acta2 −/− aortae show little to no filaments crossing the cell body, suggesting that other actin isoforms cannot substitute for SM α-actin for contractile thin filament formation in aortic SMCs. Although the pathogenesis of the subcortical structures is not known, they could result from excessive polymerization of subcortical actin in an attempt to generate cellular tension in the absence of SM α-actin filaments.
In summary, we have shown that disruption of SM α-actin filaments activates NF-κB signaling and increases expression of Agtr1a, thus potentiating signaling in the Acta2 −/− aortic SMCs with exposure to AngII. These results demonstrate a mechanism by which pathways downstream of the Agtr1a, which are established to drive aortic aneurysm formation, can be activated in the absence of increased AngII levels. Our findings suggest that losartan may attenuate aneurysm growth in patients with ACTA2 mutations but also highlight that blocking NF-κB signaling or decreasing ROS levels in aortic SMCs
